Are you currently or formerly employed by any of the following companies? Select all that apply.

Which of the following types of organizations are you currently or have you been employed with? Select all that apply.

Are you or have you been involved in market access, sales, pricing, reimbursement, or formulary decisions for Actemra or its biosimilars (e.g., Tyenne, Tofidence, etc.)?

What percentage (%) of Actemra's (tocilizumab) market share do you think biosimilars will ultimately capture? Please enter a numeric value 0-100, no special characters (%).

Do you expect biosimilar market share uptake to differ between the US and EU?

Please specify why you expect the biosimilar market share uptake to differ between the US and EU.

What level of discounting (relative to Actemra) do you think will be required for biosimilars to reach that market share? Please be specific.

Do you think the level of discounting will differ between the US and EU?

Please specify why you expect the level of discounting will differ between the US and EU.

What percentage (%) of market share do you think Tyenne (tocilizumab-aazg), a Fresenius biosimilar, will capture in the US, given it launched at the same time as Tofidence?

What percentage (%) of market share do you think Tyenne will capture in the EU, given it launched ~6 months ahead of Tofidence?

What percentage (%) of market share do you think pipeline biosimilars from Celltrion and Dr. Reddy's will capture as third and fourth entrants?

How many biosimilar competitors do you expect to ultimately enter the Actemra biosimilar market? Please enter the expected number of competitors.

Apart from being first to market, what is the biggest hurdle to achieving leading market share in early innings of biosimilar launch?

Do you think Tyenne (Fresenius biosimilar) will launch in geographies outside of United States and Europe, like Japan, etc.?

Where do you expect Tyenne (Fresenius biosimilar) will launch in geographies outside of the United States? Please be specific.